Physician profile
Paul J Roach
NPI 1760467468
$15,189.22
in general payments reported to CMS, 2019-2025
24 companies · $643 in 2025
The $643 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,158 · 2020: $1,721 · 2021: $2,285 · 2022: $2,173 · 2023: $3,290 · 2024: $918 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,876 · Travel and Lodging: $832 · Consulting Fee: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,876.06 |
| Travel and Lodging | $831.87 |
| Consulting Fee | $143.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,804.67 | 2019-2025 | Cardiomems, Assurity, Aveir |
| Heartflow, INC. | $3,055.35 | 2019-2024 | Ffrct |
| Abiomed | $1,903.60 | 2019-2023 | Impella |
| Janssen Pharmaceuticals, INC | $1,058.78 | 2019-2024 | Xarelto |
| Impulse Dynamics (USA) INC. | $952.89 | 2021-2025 | Optimizer, Optimizer |
| Sanofi-Aventis U.S. LLC | $594.87 | 2019 | |
| Boston Scientific Corporation | $522.31 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Watchman |
| Biotronik INC. | $413.71 | 2021-2022 | |
| Novo Nordisk INC | $366.86 | 2022-2024 | |
| Esperion Therapeutics, INC. | $323.61 | 2021 | |
| Amgen INC. | $323.20 | 2020-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $288.21 | 2021-2024 | |
| Cvrx, INC. | $282.19 | 2020-2022 | |
| Biosense Webster, INC. | $220.40 | 2022-2025 | Carto 3 |
| Shockwave Medical, INC | $179.47 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $156.70 | 2024 | Optowire |
| Astrazeneca Pharmaceuticals Lp | $124.95 | 2020 | |
| Medtronic Vascular, INC. | $121.49 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $117.65 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $98.49 | 2019 | |
| Atricure, INC. | $95.41 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $80.45 | 2019 | |
| Penumbra, INC. | $73.02 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $30.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.